ERS Genomics Secures Major CRISPR Patent from European Patent Office, Strengthening Its Position in Biotechnology

ERS Genomics Strengthens Its CRISPR Patent Portfolio

In a pivotal move for the biotechnology sector, ERS Genomics has announced the successful granting of a crucial CRISPR patent by the European Patent Office (EPO). This patent (EP 4 289 948) encompasses broad claims related to single guide RNAs, modified DNA-targeting RNAs, and their synergy with Cas9, marking a major victory for research and commercial applications in gene editing.

Established to facilitate broader access to foundational CRISPR intellectual property conceived by Professor Emmanuelle Charpentier, ERS Genomics aims to bolster innovation and application in the field. The EPO's decision strengthens the collective position of the parties co-owning the patent—CVC, which includes The Regents of the University of California and the University of Vienna.

John E. Milad, the CEO of ERS Genomics, expressed pride in this accomplishment, stating, "The EPO's approval of patent EP 4 289 948 with extensive claims not only affirm CVC's leadership in the European CRISPR intellectual property landscape but also validates our strategic move to self-revoke two older CRISPR/Cas9 patents. This new patent offers confidence to our over 150 licensees, while simultaneously maintaining CVC's established patent dominance in Europe."

The implication of this decision is significant; it provides enhanced security for existing licensees who utilize CRISPR technology in their research and product development. Current licensees range from major pharmaceutical companies like GSK, Merck, and Bayer to innovative biotechnology firms like Synthego and Cargill. Each benefits from access to critical patents that are essential for conducting and expanding CRISPR-based research.

ERS Genomics licenses patents that are vital for diverse applications including life sciences research tools, drug discovery, and synthetic biology projects. These licenses facilitate operations across a spectrum of endeavors, from developing novel therapeutic targets to improving health in companion animals and livestock. Therefore, this patent not only empowers existing projects but also opens new avenues for exploration and commercialization in the biotechnology field.

While focusing on advancements in Europe, Milad hints at the anticipated decision regarding CRISPR patent Interference in the U.S. Regardless of the outcome, he reassures stakeholders that foundational patents essential for CRISPR applications remain firmly under ERS Genomics' control, providing a robust platform for continued operations and innovations.

Looking ahead, the importance of this grant cannot be overstated. It serves as a catalyst for further advancements in gene editing, signaling a commitment to maintaining a stronghold in the competitive landscape of biotechnological research and applications. The endorsement from the EPO not only fortifies CRISPR's role in modern science but also represents a substantial step toward collaborative innovation in addressing global health and agricultural challenges.

For more information on ERS Genomics and their patent offerings, visit their official website www.ersgenomics.com.